Key Inclusion Criteria:

   - Diagnosis of both ABPA and asthma

   - On a maintenance therapy for their asthma with controller medication which must
   include inhaled corticosteroids (ICS) and may include 1 or more additional controller
   medications including a long-acting beta agonist (LABA), leukotriene receptor
   antagonist (LTRA), and/or long-acting muscarinic receptor antagonist (LAMA), etc for
   at least 12 weeks, with a stable dose and regimen with no change in the dose or
   frequency of administration for at least 4 weeks prior to the screening visit and
   between the screening and baseline/randomization visits

   - For participants on OCS (oral corticosteroid): must be on a chronic stable dose (no
   change in the dose) of OCS of up to 10 mg/day (for participants taking daily
   corticosteroids) or up to 30 mg every alternate day (for participants taking alternate
   day corticosteroids) (prednisone/prednisolone or the equivalent) for at least 4 weeks
   prior to the screening visit and between the screening and the baseline/randomization
   visit

   - Must have experienced ≥1 severe respiratory exacerbation requiring treatment with
   systemic corticosteroids or hospitalization or treatment in ED/urgent care within 12
   months prior to the screening visit or must be receiving chronic stable low-dose OCS
   per above criteria

Key Exclusion Criteria:

   - Weight less than 30.0 kilograms

   - Current smoker or e-cigarette user, cessation of smoking or e-cigarette use within 6
   months prior to randomization, or >=10 pack-years smoking history

   - Post-bronchodilator FEV1 <30% predicted normal at screening

   - Respiratory exacerbation requiring systemic corticosteroids within 4 weeks prior to
   screening and between screening and baseline visit (for patients on daily or alternate
   day OCS, exacerbation requiring at least double the maintenance dose of
   corticosteroids)

   - Upper or lower respiratory tract infection within the 4 weeks prior to screening
   (visit 1) or between the screening and randomization visits

   - Significant chronic pulmonary disease other than asthma complicated with ABPA (eg,
   physician-diagnosed bronchiectasis due to a condition other than ABPA; cystic
   fibrosis; sarcoidosis; interstitial lung disease not due to ABPA; chronic obstructive
   pulmonary disease [COPD] not due to ABPA; hypereosinophilic syndrome; etc), a
   diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil
   counts

   - Diagnosis or suspected diagnosis of eosinophilic granulomatosis with polyangiitis
   (EGPA) (also called Churg-Strauss Syndrome)

NOTE: Other protocol defined inclusion / exclusion criteria applies.